30 European Countries Can Offer mRNA RSV Vaccine

Moderna, Inc. announced that the European Commission (EC) has granted marketing authorization for mRESVIA®, an mRNA respiratory syncytial virus (RSV) vaccine.

RSV is a highly contagious seasonal respiratory virus that causes an exceptionally high burden of disease in infants and older adults.

As of August 23, 2024, this EC authorization is indicated to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.

The marketing authorization is valid in all 27 EU member states, as well as Iceland, Liechtenstein, and Norway.

"The EC's approval of mRESVIA is an important milestone for public health and highlights Moderna's mRNA leadership," said Stéphane Bancel, Chief Executive Officer of Moderna, in a press release.

In the European Union, RSV is estimated to cause approximately 160,000 hospital admissions in adults each year, with 92% of these admissions occurring in adults aged 65 and over.

In the United States, the RSV season has already begun in Florida and is expected to spread throughout the U.S.

For the 2024-2025 RSV season in the U.S., three vaccines and one monoclonal antibody were approved by the U.S. FDA.